SCHEMBL3766239

SCHEMBL3766239

NC1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
GAA P10253 2/20 0.49
HRH3 Q9Y5N1 5/20 0.44
SIGMAR1 Q99720 1/20 0.43
HSD17B10 Q99714 2/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.42
PARP1 P09874 1/20 0.41
POLB P06746 1/20 0.40
PHGDH O43175 1/20 0.39
MGLL Q99685 1/20 0.39
PKM P14618 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3770757 0.98 ALDH1A1 (0.50) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL3775828 0.87 KDM4E (0.65) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL13005640 0.86 KDM4E (0.68) KDM4EALDH1A1GAASIGMAR1HSD17B10
SCHEMBL3773620 0.86 KDM4E (0.68) KDM4EALDH1A1GAASIGMAR1HSD17B10
SCHEMBL3767809 0.85 SIGMAR1 (0.57) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL13005070 0.84 KDM4E (0.65) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL3769500 0.83 KDM4E (0.68) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL13005059 0.83 KDM4E (0.68) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL3774024 0.83 KDM4E (0.68) KDM4EALDH1A1GAAHRH3SIGMAR1
SCHEMBL3774221 0.83 KDM4E (0.68) KDM4EALDH1A1GAAHRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
EP-1909797-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-04-16 EP disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885GAA 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.